Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-07-24

FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc. as part of a regulatory action to modify or expand the existing app…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xtandi (enzalutamide)

Snippet

SUPPL AP for XTANDI (ENZALUTAMIDE)